

Roberto Ferrara

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/690625/roberto-ferrara-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

63

papers

2,922

citations

22

h-index

54

g-index

67

ext. papers

3,880

ext. citations

5.3

avg, IF

5.25

L-index

#	Paper	IF	Citations
63	Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy.. <i>Cancers</i> , 2022 , 14,	6.6	4
62	Genomics and Immunomics in the Treatment of Urothelial Carcinoma. <i>Current Oncology</i> , 2022 , 29, 3499-3518	3.8	0
61	Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. <i>Cancers</i> , 2021 , 13,	6.6	2
60	Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 160, 103299	7	3
59	Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments. <i>Cellular Immunology</i> , 2021 , 362, 104301	4.4	0
58	Myeloid cell heterogeneity in lung cancer: implication for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 2429-2438	7.4	3
57	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2021 , 4, CD013257	5.2	8
56	Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis. <i>Immunotherapy</i> , 2021 , 13, 621-631	3.8	16
55	Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. <i>Translational Lung Cancer Research</i> , 2021 , 10, 2955-2969	4.4	0
54	Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. <i>Clinical Cancer Research</i> , 2021 , 27, 492-503	12.9	31
53	Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. <i>Lung Cancer</i> , 2021 , 152, 165-173 ^{5.9}	5.9	11
52	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2020 , 12, CD013257	5.2	12
51	Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020 , 6, 1039-1046	13.4	36
50	DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. <i>Clinical Lung Cancer</i> , 2020 , 21, e337-e348	4.9	4
49	Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?.. <i>Oncologist</i> , 2020 , 25, 94-98	5.7	26
48	Facing the First-line in Metastatic Non-small-cell Lung Cancer [Immunotherapy and Chemotherapy. <i>European Oncology and Haematology</i> , 2020 , 16, 39	0.1	
47	Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2020 , 122, 340-347	8.7	15

46	Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI). <i>Cancers</i> , 2020 , 12,	6.6	14
45	Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy.. <i>JCO Precision Oncology</i> , 2020 , 4, 829-840	3.6	5
44	Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. <i>Translational Lung Cancer Research</i> , 2020 , 9, 617-628	4.4	3
43	Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer. <i>Cancers</i> , 2020 , 12,	6.6	14
42	Atypical patterns of response and progression in the era of immunotherapy combinations. <i>Future Oncology</i> , 2020 , 16, 1707-1713	3.6	7
41	Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2020 , 22, 41	6.3	10
40	Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2019 , 137, 38-42	5.9	29
39	Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. <i>European Journal of Cancer</i> , 2019 , 109, 28-35	7.5	50
38	Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019 , 116, 182-189	7.5	23
37	Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer-In Reply. <i>JAMA Oncology</i> , 2019 , 5, 744	13.4	4
36	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. <i>ESMO Open</i> , 2019 , 4, e000457	6	93
35	Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. <i>Cancer Treatment Reviews</i> , 2019 , 75, 39-51	14.4	85
34	Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1244-1254	8.9	106
33	Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. <i>Future Oncology</i> , 2019 , 15, 2743-2757	3.6	5
32	The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma. <i>Clinical Lung Cancer</i> , 2019 , 20, e652-e660	4.9	2
31	Single or combined immune checkpoint inhibitors compared to first-line chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2019 ,	5.2	2
30	Fast-progression (FP), hyper-progression (HPD) and early deaths (ED) in advanced non-small cell lung cancer (NSCLC) patients (pts) upon PD-(L)-1 blockade (IO).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9107-9107	2.2	7
29	How to recognize and manage hyper-progression and pseudo- progression during immune checkpoint blockade in non-small cell lung cancer. <i>Precision Cancer Medicine</i> , 2019 , 2, 35-35	1	1

28	EPSILON: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. <i>Cancers</i> , 2019 , 11,	6.6	39
27	Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients. <i>European Journal of Cancer</i> , 2019 , 108, 88-96	7.5	22
26	Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2019 , 106, 144-159	7.5	108
25	Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers-Letter. <i>Clinical Cancer Research</i> , 2019 , 25, 3468	12.9	13
24	Progress in the Management of Advanced Thoracic Malignancies in 2017. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 301-322	8.9	34
23	The development of PARP as a successful target for cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 161-175	3.5	12
22	Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018 , 4, 351-357	13.4	357
21	Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9003-9003	2.2	12
20	Impact of central nervous system (CNS) involvement in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9066-9066	2.2	
19	Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. <i>European Journal of Cancer</i> , 2018 , 88, 38-47	7.5	178
18	Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 27-45	8.9	90
17	Prognostic value of histogram analysis in advanced non-small cell lung cancer: a radiomic study. <i>Oncotarget</i> , 2018 , 9, 1906-1914	3.3	10
16	Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2872-2878	2.2	477
15	Do immune checkpoint inhibitors need new studies methodology?. <i>Journal of Thoracic Disease</i> , 2018 , 10, S1564-S1580	2.6	35
14	Hyperprogressive disease: recognizing a novel pattern to improve patient management. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 748-762	19.4	206
13	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. <i>JAMA Oncology</i> , 2018 , 4, 1543-1552	13.4	380
12	Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?. <i>Cancer Treatment Reviews</i> , 2017 , 60, 60-68	14.4	83
11	Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. <i>Journal of Pathology</i> , 2017 , 241, 488-500	9.4	122

10	Afatinib in patients with metastatic HER2-mutant lung cancers: An international multicenter study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9071-9071	2.2	12
9	Baseline-derived neutrophil-to-lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) to predict the benefit of immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9089-9089	2.2	1
8	Tubulin inhibitors in non-small cell lung cancer: looking back and forward. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1113-29	4	18
7	ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. <i>Respiratory Research</i> , 2016 , 17, 105	7.3	9
6	Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2253-2266	4	22
5	The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 1359-70	5.4	11
4	An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 1143-61	5.9	5
3	Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report. <i>Future Science OA</i> , 2015 , 1, FSO29	2.7	2
2	Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a new frontier?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2015 , 15, 307-13	2.2	10
1	Prognostic value of ALK gene copy number (GCN) status for resected and metastatic non-small-cell lung cancer (NSCLC): A retrospective analysis of 205 patients (pts).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e19059-e19059	2.2	